March 2019

Dr. Annalisa Jenkins is appointed Non-Executive Chairman on Phaim's Board of Directors

Dr. Annalisa Jenkins is a life sciences thought leader with over 20 years of biopharmaceutical industry experience. Prior to joining PlaqueTec as CEO in November 2017, Dr. Jenkins served as president and CEO of Dimension Therapeutics, a leading gene therapy company that was acquired by Ultragenyx in November 2017. Prior leadership roles have included the head of global research and development and executive vice president global development and medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years, including serving as senior vice president and head of global medical affairs. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander.

Dr. Jenkins is a board member of several growing companies, including Phaim, Ardelyx, Inc., iOX Therapeutics Limited, Thrombolytic Strategies Incorporated, PhESi, Oncimmune, Cocoon Biotech Inc.(Non Executive Chair), Cellmedica (Non-Executive Chair), Vium Inc.(Executive Chair), and Silence Therapeutics (Non-Executive Chair). She also is a committee member of the Science Board to the U.S. Food & Drug Administration (FDA), and serves on the board of the Center for Talent Innovation in the U.K. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital in the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.